Enhanced spontaneous thrombolysis: A new therapeutic challenge.
Am Heart J. 2006 Jun; 21(3):221-227. Kovacs IB, Gorog DA, Yamamoto J. |
Increased plasma plasminogen activator inhibitor-1 levels caused by additional aspirin treatment.
Thromb Haemost. 2006 May; 95(5):906-7. Sakata T, Kario K. |
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction.
N Engl J Med. 2006 Mar; Epub ahead of print Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. |
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Diabetologia.. 2006 Mar; Epub ahead of print Dunn EJ, Philippou H, Ariens RA, Grant PJ |
Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
Thromb Haemost.. 2006 Mar; 95(3):585-6. Belmar JV, Marco P, Benlloch S, Sanchez J, Lucas J. |
Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal.
Arch Gynecol Obstet. . 2006 Mar; 273(6):322-4 Epub 2006 Jan 28.. Wiwanitkit V. |
Fibrinolysis and cardiovascular risk factors: Association with fibrinogen, lipids, and monocyte count.
Eur J Intern Med. . 2006 Mar; 17(2):102-8. Zouaoui Boudjeltia K, Guillaume M, Henuzet C, Delree P, Cauchie P, Remacle C, Ducobu J, Vanhaeverbeek M, Brohee D. |
Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review.
Crit Care Med. . 2006 Mar; 34(3):871-7. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. |
The association between factor XIII Val34Leu polymorphism and early myocardial infarction.
Circ J.. 2006 Mar; 70(3):239-42. Hancer VS, Diz-Kucukkaya R, Bilge AK, Ozben B, Oncul A, Ergen G, Nalcaci M. |
Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
Biochemistry. . 2006 Feb; 45(8):2657-67. Doolittle RF, Pandi L. |
Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis: A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia.
Biochemistry.. 2006 Feb; 45(8):2480-2487. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M |
Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator.
Stroke.. 2006 Feb; Epub ahead of print Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera JA, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta JL. |
Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Transplant Proc. . 2006 Feb; 38(1):105-7. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. |
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
Curr Diab Rep.. 2006 Feb; 6(1):47-54. Trost S, Pratley R, Sobel B. |
Molecular basis of fibrinogen deficiency.
Pathophysiol Haemost Thromb. 2006 Ene; 35(1-2):187-98. Neerman-Arbez M. |
Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Ann Med. 2006 Ene; 38(6):378-88. Bouma BN, Mosnier LO. |
TAFI and PAI-1 levels in human sepsis
Thromb Res. 2005 Jul; Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA |
Studies on the basis for the properties of fibrin produced from fibrinogen containing {gamma}´ chains.
Blood. 2005 Jul; Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, Diorio JP, Stojanovic L |
Bleeding diathesis in a child with normal screening tests: think about fibrinolysis
Eur J Pediatr. 2005 Jun; Largent V, Deneys V, Brichard B, Chantrain C, Vermylen C |
A new functional assay of thrombin activatable fibrinolysis inhibitor
J Thromb Haemost. 2005 Jun; 3(6):1284-92. Guimaraes AH, Bertina RM, Rijken DC |